Evolus, Inc. (NASDAQ: EOLS) filed a Current Report on Form 8-K on August 4, 2026, disclosing that its wholly owned subsidiary Evolus Pharma B.V. entered into an amendment to its existing License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. on August 3, 2026.

Key Highlights

  • Territory expansion: The amendment adds Canada and Australia and New Zealand combined to the existing agreement between Evolus Europe and Symatese.
  • Product covered: Evolus Europe receives exclusive rights to commercialize and distribute the full line of Estyme-branded injectable hyaluronic acid gels in the new territories.
  • Upfront payment: Evolus Europe is required to pay €920,000 in upfront signing payments as consideration for the additional rights.
  • Milestone payments: Up to an additional €1.38 million may be owed upon receipt of certain regulatory approvals.
  • Regulatory responsibility: Symatese will be responsible, at its expense, for development and regulatory activities required to obtain and maintain approvals in the new territories.
  • Initial term: The term for each new territory is 15 years from the first applicable regulatory approval, with automatic renewal for successive five-year terms.

Evolus Europe Adds New Markets for Estyme Hyaluronic Acid Gels

According to the filing, Evolus Pharma B.V., a wholly owned subsidiary of Evolus, Inc., entered the amendment on August 3, 2026, with Symatese Aesthetics S.A.S. The underlying License, Supply and Distribution Agreement was originally dated December 20, 2023, and was previously disclosed in a Current Report filed on that same date. The amendment modifies that agreement to extend the covered territory to include Canada and Australia and New Zealand combined, and grants Evolus Europe exclusive commercialization and distribution rights to the full line of Estyme-branded injectable hyaluronic acid gels in those regions.

As consideration for the additional rights, the filing states that Evolus Europe is required to pay €920,000 in upfront signing payments, with up to an additional €1.38 million payable upon receipt of certain regulatory approvals. Symatese will bear, at its own expense, all development and regulatory activities needed to secure and maintain approvals in the newly added territories. The filing notes that the initial term for each new territory runs 15 years from the first applicable regulatory approval and will automatically renew for successive five-year terms, subject to the terms of the existing agreement.

The company also disclosed under Item 7.01 that it issued a press release on August 4, 2026 announcing the amendment. The press release was furnished as Exhibit 99.1 to the Form 8-K. The filing notes that the full text of the amendment will be filed as an exhibit to the company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The Form 8-K was signed by David Moatazedi, President and Chief Executive Officer of Evolus, Inc.

What Was Disclosed

Evolus, Inc. disclosed an amendment to its Symatese license agreement that extends covered territories to Canada and Australia and New Zealand, with €920,000 in upfront payments and up to €1.38 million in potential milestone payments tied to regulatory approvals.